AbbVie will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), a novel biomarker-specific therapy derived from cancer stem cells.
Caroline Hroncich
Advertisement
Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.
Articles by Caroline Hroncich
The National Institutes of Health (NIH) released a statement on April 19, 2016 saying that it plans to suspend research in two laboratories after preliminary results found the labs not in compliance with CGMP practices.
The IMS Institute for Healthcare Informatics report examines spending on medicine in the US, drivers of growth, major market segments, prescription volume, patient costs, and healthcare delivery changes.
Advertisement
Latest Updated Articles
- IMS Institute Report Examines Medicine Use and Spending in 2015
Published: April 14th 2016 | Updated:
- NIH Suspends Research in Sterile Production Facilities
Published: April 20th 2016 | Updated:
- AbbVie to Acquire Stemcentrx
Published: April 28th 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress
5
